|
|
UCB Presents New LongTerm Data Showing Substantial Impact for CIMZIA® Certolizumab Pegol in Axial Spondyloarthritis and Rheumatoid Arthritis and LateBreaking Bimekizumab Data in Psoriatic ArthritisOral presentation of results from CAXSPAND, the first Phase 3 study to follow nonradiographic axial spondyloarthritis nraxSpA patients for 52 weeks, demonstrated positive results for CIMZIA®... See more |
|
|
|
| |
|
| |
|
|
The impact of fragility fractures due to osteoporosis is being ignoredNew survey reveals that 61 per cent of women over 60 have little or no knowledge of osteoporosis, despite the fact that one in three is likely to develop a fragility fracture due to the conditionOver half 55 per cent of respondents believe that fragility fractures in older age are a result of an unlucky fall or accident, rather... See more |
|
|
|
| |
|
| |
|
|
UCB Accelerates AntiFcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development PhasePositive outcomes in proofofconcept study with subcutaneous rozanolixizumab in patients with myasthenia gravis MG: clinically meaningful improvement in multiple diseaserelated endpointsStrong 68% mean reduction of Serum IgG and IgG Autoantibodies observedSafety profile inline with subcutaneous dosing... See more |
|
|
|
| |
|
| |
|
|
Transparency notifications BlackRock, Inc.2 notifications referring to situation on 2 October and 3 October 2018Threshold crossed: 5%Latest holding: 4.998%Brussels Belgium, 5 October 2018 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2... See more |
|
|
|
| |
|
| |
|
|
Search :
